Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies. Pfizer’s GMG competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the practice gaps as outlined in the specific RFP. For all independent quality improvement grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct or monitoring of the quality improvement program.
The aim of this RFP is to support three Quality Improvement (QI) Projects that will enhance systems of care or implement new tools that will optimize early therapy management for patients with CML. The intent of the RFP is to support one project in Canada and two in the United States.
Proposals should:
- Engage a multi-disciplinary team to identify and implement improvements in systems of care
- Incorporate patient’s perspectives and participation in CML therapy management
- Develop QI tools to support clinicians / patients in first ~90 days of TKI treatment for patients
- Establish a plan for widely sharing best practices and QI tools that come from the project